Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erleada in Biochemically Relapsed Hormone Sensitive Prostate Cancer
NCT01790126Phase 2Completed
- Sponsor
- Aragon Pharmaceuticals
- Start
- Mar 2013
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by Aragon Pharmaceuticals. Started Mar 2013; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01790126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01790126.